An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
In the population experiencing an FCTO, base-case results for ustekinumab (every eight weeks and every 12 weeks) were sensitive to the proportion of patients with 16 weeks in the nonresponse health state who underwent surgery, to the remission and nonresponse utility values used, and finally to the efficacy of the additional induction dose. For results in the population experiencing a failure with anti-TNF therapy, the most sensitive parameters were the remission utility value, the efficacy of the additional induction dose, and the probability of surgery after 16 weeks in the nonresponse health state.
The manufacturer conducted a scenario analysis comparing ustekinumab with conventional therapy with alternative costing for ustekinumab medication costs, including such aspects as rebates, free induction dose, annual-patient expenditure caps, and free ustekinumab after loss of response after surgery (Appendix 3, Table 12).
The manufacturer did not present a sensitivity analysis for the mixed population.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
